Page last updated: 2024-10-30

losartan and Schistosomiasis mansoni

losartan has been researched along with Schistosomiasis mansoni in 2 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Schistosomiasis mansoni: Schistosomiasis caused by Schistosoma mansoni. It is endemic in Africa, the Middle East, South America, and the Caribbean and affects mainly the bowel, spleen, and liver.

Research Excerpts

ExcerptRelevanceReference
"Schistosomiasis mansoni is involved in hepatic fibrogenesis and portal hypertension."1.48The comparative efficacy of renin-angiotensin system blockers in schistosomal hepatic fibrosis. ( Augusto, MJ; Elias Júnior, J; Parreira, NA; Prado, CM; Ramalho, FS; Ramalho, LNZ; Rodrigues, V; Silva, DM, 2018)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Parreira, NA1
Ramalho, FS1
Augusto, MJ1
Silva, DM1
Prado, CM1
Elias Júnior, J1
Rodrigues, V1
Ramalho, LNZ1
El-Lakkany, NM1
El-Maadawy, W1
Ain-Shoka, A1
Badawy, A1
Hammam, O1
Ebeid, F1

Other Studies

2 other studies available for losartan and Schistosomiasis mansoni

ArticleYear
The comparative efficacy of renin-angiotensin system blockers in schistosomal hepatic fibrosis.
    Experimental parasitology, 2018, Volume: 191

    Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals;

2018
Potential antifibrotic effects of AT1 receptor antagonist, losartan, and/or praziquantel on acute and chronic experimental liver fibrosis induced by Schistosoma mansoni.
    Clinical and experimental pharmacology & physiology, 2011, Volume: 38, Issue:10

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anthelmintics; Disease Models, Animal; Drug Therap

2011